[The effect of benzbromarone on fasting-hyperuricemia as a model (author's transl)].
The effect of daily therapeutic doses of 100 mg benzbromarone (Normurat) and 2.0 g probenecid on the purine metabolism of 40 test subjects was investigated. Fasting-hyperuricemia was used as the model and particular attention paid to the mechanisms of renal elimination. Urate concentration remains under the solubility threshold when benzbromarone is administered, in contrast to medication with probenecid. The significantly greater hypouricemic effect of benzbromarone correlates with a significant rise in the excretion and clearance of uric acid in comparison to probenecid, accompanied by a stronger depression of tubular reabsorption. Serum levels, clearances and reabsorption rates demonstrate the prolonged effect of the benzofurane derivative Normurat even during strict fasting. Supplementary allantoin and urea determinations gave no indication of increased enterobacterial uricolysis. Normurat was well tolerated, side effects were not noted.
D000293:Adolescent; D000328:Adult; D001553:Benzbromarone / Q000494:pharmacology* / Q000627:therapeutic use; D001572:Benzofurans / Q000494:pharmacology*; D005215:Fasting; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000628:therapy; D011339:Probenecid / Q000494:pharmacology; D011687:Purines / Q000378:metabolism*; D014527:Uric Acid / Q000652:urine
D001572:Benzofurans; D011687:Purines; D014527:Uric Acid; D001553:Benzbromarone; D011339:Probenecid
Zur Wirkung von Benzbromaron am Modell der "Fastenhyperurikämie".